Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR imaging of extraocular muscle and orbital fat thickness to predict glucocorticoid efficacy in Graves' orbitopathy
ChiCTR-RPC-16008209Phase 4Recruiting
- Sponsor
- Southern Medical University
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone in Graves' ophthalmopathy (TED) (3 arms), sponsored by Southern Medical University. Primary endpoints: Thickness of extraocular muscle and Orbital fat thickness. Started Apr 2016; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on ChiCTR-RPC-16008209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RPC-16008209.